CooperCompanies Announces MiSight® Approval in China
August 12 2021 - 9:00AM
CooperCompanies (NYSE: COO), today announced that the Chinese
National Medical Products Administration (NMPA), which regulates
medical devices and pharmaceuticals in China, has approved
CooperVision MiSight® 1 day contact lenses for use within the
country following a priority review.
“We are extremely excited to receive this approval,” said Al
White, President and CEO. “The increasing incidence of myopia is
one of the most pressing global eye-health issues we face today,
and receiving approval from the NMPA allows us to work closely with
eye-care professionals proactively treating children in China.
MiSight® is the most innovative contact lens in the market, and we
remain incredibly passionate about promoting it along with our
ortho-k and SightGlass Vision® myopia management products.”
MiSight® is the first Chinese NMPA approved soft contact lens
with an indication relating to slowing the progression of axial
length in patients who at initiation are 8-12 years old and have a
refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of
astigmatism. Myopia (nearsightedness or short-sightedness)
progression has been linked to causing cataracts, retinal
detachment, glaucoma and myopic maculopathy later in life. Within
China, the prevalence of myopia among high school students is
estimated to be around 80 percent. Additional information may be
found at CooperVision.com and in the CooperVision MiSight® trade
release.
The company will provide further information on its September 2,
2021 earnings call.
About CooperCompaniesCooperCompanies ("Cooper")
is a global medical device company publicly traded on the NYSE
(NYSE: COO). Cooper operates through two business units,
CooperVision and CooperSurgical. CooperVision brings a refreshing
perspective on vision care with a commitment to developing a wide
range of high-quality products for contact lens wearers and
providing focused practitioner support. CooperSurgical is committed
to advancing the health of women, babies and families with its
diversified portfolio of products and services focusing on medical
devices and fertility & genomics. Headquartered in San Ramon,
CA, Cooper has a workforce of more than 12,000 with products sold
in over 100 countries. For more information, please visit
www.coopercos.com.
Contact:Kim DuncanVice President, Investor Relations and Risk
Management925-460-3663ir@cooperco.com
Cooper Companies (NYSE:COO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cooper Companies (NYSE:COO)
Historical Stock Chart
From Apr 2023 to Apr 2024